Literature DB >> 26558391

99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.

Lilian Yuri Itaya Yamaga1, Guilherme Campos Carvalho Neto2, Marcelo Livorsi da Cunha2, Akemi Osawa2, Julio Cesar Silveira Oliveira2, Ricardo Quartim Fonseca2, Solange Amorim Nogueira2, Jairo Wagner2, Marcelo Gusmão Funari2.   

Abstract

OBJECTIVE: The aim of this study was to assess the occurrence and frequency of increased physiologic uptake of 99mTc-HYNIC-TOC by the uncinate process of the pancreas in SPECT/CT images.
METHODS: Forty-six scans of 41 patients were evaluated retrospectively. The uptake of 99mTc-HYNIC-TOC was considered to be physiologic in patients with normal findings at dedicated abdominal CT or MR and lack of neoplastic lesions in clinical follow-ups. The intensity of uncinate process uptake was compared to the uptake of the normal liver.
RESULTS: Focal uptake was attributed to the presence of pancreatic NET in 5 patients. Among the 36 patients without any evidence of malignancy in CT, MR and follow-up, 7 (19.4 %) showed increased uptake in the uncinate process. The intensity of uptake was lesser in 3 (8.3 %), similar in 3 and greater than the normal liver in 1 (2.8 %) case.
CONCLUSION: Increased 99mTc-HYNIC-TOC uptake occurred in 19.4 % of those subjects without any evidence of neuroendocrine tumor in the uncinate process.

Entities:  

Keywords:  99mTc-HYNIC-Tyr3-octreotide; Neuroendocrine tumors; SPECT-CT; Somatostatin receptor imaging

Mesh:

Substances:

Year:  2015        PMID: 26558391     DOI: 10.1007/s11547-015-0593-2

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  10 in total

1.  Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study.

Authors:  Yusuke Taniyama; Takashi Suzuki; Yoshiki Mikami; Takuya Moriya; Susumu Satomi; Hironobu Sasano
Journal:  Endocr J       Date:  2005-10       Impact factor: 2.349

2.  Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

Authors:  Matthias Miederer; Stefan Seidl; Andreas Buck; Klemens Scheidhauer; Hans-Jürgen Wester; Markus Schwaiger; Aurel Perren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-20       Impact factor: 9.236

3.  Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT.

Authors:  Paolo Castellucci; Javier Pou Ucha; Chiara Fuccio; Domenico Rubello; Valentina Ambrosini; Gian Carlo Montini; Vincenzina Pettinato; Claudio Malizia; Filippo Lodi; Stefano Fanti
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

4.  68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.

Authors:  Valentina Ambrosini; Davide Campana; Lisa Bodei; Cristina Nanni; Paolo Castellucci; Vincenzo Allegri; Gian Carlo Montini; Paola Tomassetti; Giovanni Paganelli; Stefano Fanti
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

5.  68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Authors:  A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-05       Impact factor: 9.236

6.  Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.

Authors:  Jolanta Kunikowska; Leszek Królicki; Dariusz Pawlak; Imene Zerizer; Renata Mikołajczak
Journal:  Clin Nucl Med       Date:  2012-11       Impact factor: 7.794

7.  99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

Authors:  C Decristoforo; S J Mather; W Cholewinski; E Donnemiller; G Riccabona; R Moncayo
Journal:  Eur J Nucl Med       Date:  2000-09

8.  An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.

Authors:  Michael Gabriel; Clemens Decristoforo; Eveline Donnemiller; Hanno Ulmer; Christine Watfah Rychlinski; Stephen J Mather; Roy Moncayo
Journal:  J Nucl Med       Date:  2003-05       Impact factor: 10.057

9.  Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.

Authors:  Ka Kit Wong; John M Cahill; Kirk A Frey; Anca M Avram
Journal:  Acad Radiol       Date:  2009-12-04       Impact factor: 3.173

Review 10.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08
  10 in total
  5 in total

1.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

2.  Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold.

Authors:  Jamal J Derakhshan; Michael D Farwell
Journal:  Nucl Med Commun       Date:  2019-07       Impact factor: 1.690

3.  99mTc-Hynic-TOC imaging in the diagnostic of neuroendocrine tumors.

Authors:  Knut Liepe; Andreas Becker
Journal:  World J Nucl Med       Date:  2018 Jul-Sep

4.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020

Review 5.  Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Authors:  Maria Isabel Del Olmo-Garcia; Stefan Prado-Wohlwend; Alexia Andres; Jose M Soriano; Pilar Bello; Juan Francisco Merino-Torres
Journal:  Biomedicines       Date:  2021-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.